May 14, 2020 / 12:20PM GMT
Gregory Allen Harrison - BofA Merrill Lynch, Research Division - Research Analyst
Hello, everyone. Welcome to the morning session of day 3 of the Bank of America Virtual Vegas Health Care Conference. I'm Greg Harrison, U.S. biopharma analyst here at BofA. And I'm very excited that we have Athersys with us today. Here to speak on behalf of Athersys is Chairman and CEO, Gil Van Bokkelen. And if you'd like to send questions, I can read them anonymously at the end, after the presentation.
And with that, I'll hand it over to Gil.
Gil Van Bokkelen - Athersys, Inc. - Co-Founder, Chairman & CEO
Thanks, Greg. It's a pleasure to be part of the 2020 Bank of America Health Care Conference and to have the opportunity to present today. To begin with, as shown on Slide 2, I will be making some statements in the presentation today that are covered under safe harbor and refer you to our SEC filings for additional information. To summarize on Slide 3, Athersys has been recognized internationally as an established leader in the regenerative medicine area for more than
Athersys Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot